Komipharm International Co. Ltd (041960) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Komipharm International Co. Ltd (041960) has a cash flow conversion efficiency ratio of 0.013x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩946.94 Million ≈ $641.73K USD) by net assets (₩72.06 Billion ≈ $48.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Komipharm International Co. Ltd to measure how much of total assets are equity-financed.
Komipharm International Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Komipharm International Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 041960 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Komipharm International Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Komipharm International Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Sainty Corp Ltd
SHG:600287
|
-0.022x |
|
TianJin JinRong TianYu Precision Machinery Inc.
SHE:300988
|
0.019x |
|
Palram
TA:PLRM
|
0.047x |
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
-0.001x |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
0.041x |
|
MM Forgings Limited
NSE:MMFL
|
0.196x |
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009415
|
-0.073x |
|
Federal-Mogul Goetze (India) Limited.
NSE:FMGOETZE
|
0.049x |
Annual Cash Flow Conversion Efficiency for Komipharm International Co. Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Komipharm International Co. Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 041960 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩72.06 Billion ≈ $48.83 Million |
₩-621.80 Million ≈ $-421.39K |
-0.009x | -106.39% |
| 2024-12-31 | ₩65.54 Billion ≈ $44.41 Million |
₩8.85 Billion ≈ $6.00 Million |
0.135x | +389.35% |
| 2023-12-31 | ₩60.02 Billion ≈ $40.67 Million |
₩-2.80 Billion ≈ $-1.90 Million |
-0.047x | -56.46% |
| 2022-12-31 | ₩60.63 Billion ≈ $41.09 Million |
₩-1.81 Billion ≈ $-1.23 Million |
-0.030x | -57.78% |
| 2021-12-31 | ₩66.46 Billion ≈ $45.04 Million |
₩-1.26 Billion ≈ $-851.13K |
-0.019x | -5819.79% |
| 2020-12-31 | ₩76.28 Billion ≈ $51.69 Million |
₩25.20 Million ≈ $17.08K |
0.000x | -97.45% |
| 2019-12-31 | ₩73.28 Billion ≈ $49.66 Million |
₩950.79 Million ≈ $644.34K |
0.013x | +160.06% |
| 2018-12-31 | ₩93.39 Billion ≈ $63.29 Million |
₩-2.02 Billion ≈ $-1.37 Million |
-0.022x | -1028.56% |
| 2017-12-31 | ₩101.27 Billion ≈ $68.63 Million |
₩235.64 Million ≈ $159.69K |
0.002x | -82.06% |
| 2016-12-31 | ₩93.20 Billion ≈ $63.16 Million |
₩1.21 Billion ≈ $819.00K |
0.013x | +133.70% |
| 2015-12-31 | ₩76.13 Billion ≈ $51.59 Million |
₩-2.93 Billion ≈ $-1.98 Million |
-0.038x | +19.33% |
| 2014-12-31 | ₩53.16 Billion ≈ $36.02 Million |
₩-2.54 Billion ≈ $-1.72 Million |
-0.048x | -154.21% |
| 2013-12-31 | ₩44.72 Billion ≈ $30.31 Million |
₩3.93 Billion ≈ $2.67 Million |
0.088x | -- |
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more